Jaguar Animal Health Inc (JAGX)
$0.32
$-0.05
(-12.91%)
As on 10-Sep-2026 16:29EDT
Market cap
$3 Mln
Revenue (TTM)
$28 Mln
P/E Ratio
0
P/B Ratio
0.6
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-5.5 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.6
-
Debt to Equity
0.3
-
Book Value
$--
-
EPS
$-334.7
-
Face value
--
-
Shares outstanding
5,168,300
10 Years Aggregate
CFO
$-203.80 Mln
EBITDA
$-198.88 Mln
Net Profit
$-318.09 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Jaguar Animal Health Inc (JAGX)
| -99.0 | -66.4 | -88.7 | -99.5 | -89.8 | -92.9 | -83.0 |
|
BSE Sensex*
| -12.2 | -5.4 | 0.5 | -8.7 | 3.7 | 5.0 | 9.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Jaguar Animal Health Inc (JAGX)
| -96.3 | 558.6 | -97.7 | -91.6 | -57.5 | 1.7 | -95.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Jaguar Animal Health Inc (JAGX)
|
0.3 | 3.1 | 27.8 | -36.7 | -46.3 | -- | 0 | 0.6 |
| 82.8 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 261.2 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 73.6 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 57.4 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 107.0 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 345.6 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.0 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 533.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 583.2 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Jaguar Animal Health Inc (JAGX)
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The... company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California. Read more
-
Founder, CEO, President & Director
Ms. Lisa A. Conte
-
Founder, CEO, President & Director
Ms. Lisa A. Conte
-
Headquarters
San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Jaguar Animal Health Inc (JAGX)
What is the current share price of Jaguar Animal Health Inc (JAGX) Today?
The share price of Jaguar Animal Health Inc (JAGX) is $0.32 (NASDAQ) as of 10-Sep-2026 16:29 EDT. Jaguar Animal Health Inc (JAGX) has given a return of -89.76% in the last 3 years.
What is the current PB & PE ratio of Jaguar Animal Health Inc (JAGX)?
The P/E ratio of Jaguar Animal Health Inc (JAGX) is 0.01 times as on 04-Sep-2026.
The P/B ratio of Jaguar Animal Health Inc (JAGX) is 0.57 times as on 04-Sep-2026, a 89 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
0.00 |
-0.01 |
2024 |
-0.01 |
0.04 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
-0.29 |
2021 |
-- |
-- |
What is the 52 Week High and Low of Jaguar Animal Health Inc (JAGX)?
The 52-week high and low of Jaguar Animal Health Inc (JAGX) are Rs 85.40 and Rs 0.31 as of 11-Sep-2026.
What is the market cap of Jaguar Animal Health Inc (JAGX)?
Jaguar Animal Health Inc (JAGX) has a market capitalisation of $ 3 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Jaguar Animal Health Inc (JAGX)?
Before investing in Jaguar Animal Health Inc (JAGX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.